SURVEY OF HEART FAILURE TREATMENT STATUS ACCORDING TO VIETNAM HEART ASSOCIATION GUIDELINES AT TRƯNG VƯƠNG HOSPITAL
Main Article Content
Abstract
Objective: To determine the adherence to the Vietnam Heart Association’s heart failure treatment guidelines at Trưng Vương Hospital.
Methods: A cross-sectional descriptive study was conducted on 119 heart failure with reduced ejection fraction outpatients. Logistic and linear regression analyses were utilized to identify factors associated with left ventricular ejection fraction classification and the total number of foundational medication classes prescribe.
Results: High prescription rates were recorded for foundational classes: renin-angiotensin system inhibitors (92.4%), SGLT2 inhibitors (90.7%), mineralocorticoid receptor antagonists (84.8%), and beta-blockers (82.4%). Notably, 61.3% of patients achieved the “four-pillar” combination therapy. SGLT2 inhibitors achieved an optimal target dose rate of 89,9%. Conversely, target dose achievement for ACEi/ARB/ARNI, beta-blockers, and MRAs remained below 1%. Chronic kidney disease was the only statistically significant barrier reducing the number of combined medication classes (B = -0.670; p < 0.001).
Conclusion: Trung Vuong Hospital has achieved success in implementing early multi-therapy for heart failure patients, highlighting the advantages of SGLT2i in patients with smaller body habitus. However, the low rate of target dose achievement for conventional therapies necessitates individualized titration strategies.
Article Details
Keywords
Heart failure with reduced ejection fraction, renin-angiotensin system inhibitors, SGLT2 inhibitors, aldosterone antagonist diuretics, beta-blockers.
References
[2] Greene S.J, Butler J, Albert N.M et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. Journal of the American College of Cardiology, 2018, 72 (4): 351-366. doi: 10.1016/j.jacc.2018.04.070.
[3] Linssen G.C, Van der Meer P. Regional variations in heart failure care: Evidence from the CHECK-HF registry. JACC: heart failure, 2022, 10 (4), 278-287. doi: 10.1016/j.jchf.2022.01.003.
[4] Lê Minh Trí. Điều trị suy tim phân suất tống máu giảm theo khuyến cáo Hội Tim mạch Việt Nam tại Bệnh viện Tim Tâm Đức. Luận văn bác sĩ chuyên khoa II, Trường Đại học Y khoa Phạm Ngọc Thạch, 2023.
[5] Mai Xuân Tiến, Trần Kim Trang, Vũ Mạnh Nhân. Sử dụng thuốc ức chế SGLT2 ở bệnh nhân suy tim mạn phân suất tống máu giảm theo khuyến cáo của Hội Tim mạch học Việt Nam 2022. Tạp chí Y học Việt Nam, 2025, 546 (3): 325-329. doi: 10.51298/vmj.v546i3.12767.
[6] Nguyễn Ngọc Thanh Vân và cộng sự. Khảo sát điều trị suy tim theo khuyến cáo của Hội Tim mạch châu Âu. Tạp chí Y học thành phố Hồ Chí Minh, 2021, 25 (2): 35-41. doi: 10.34810/vjs2021206.
[7] Patil T, Ali S, Kaur A et al. Impact of pharmacist-led heart failure clinic on optimization of guideline-directed medical therapy (PHARM-HF). Journal of Cardiovascular Translational Research, 2022, 15 (6): 1424-1435. doi: 10.1007/s12265-022-10262-9.
[8] Bộ Y tế. Quyết định số 1857/QĐ-BYT ngày 05 tháng 7 năm 2022: Quyết định về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị suy tim cấp và mạn”.
[9] MacDonald M.R, Tay W.T et al. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: Outcomes in the ASIAN‐HF registry. Journal of the American Heart Association, 2020, 9 (1): e012199. doi: 10.1161/JAHA.119.012199.